Local Reaction to Allergy Shot: Identification, Grading and Home Management

A normal local reaction to an allergy shot is a small, circular area of redness and mild swelling at the injection site — typically smaller than a U.S. quarter (about 2.5 cm in diameter). The skin may feel warm and itchy, and the area may be mildly tender when touched. The reaction usually develops within 20-30 minutes of the injection as mast cells at the injection site release histamine in response to the allergen extract. In most cases, the redness and swelling resolve on their own within 1-3 hours. A mild late-phase response may cause some additional swelling that develops 6-12 hours later, typically resolving within 24 hours. This pattern is expected and is not a sign that anything is wrong with your treatment or that your body is reacting dangerously.

Report to your allergist before the next injection if the reaction swelling is larger than your palm (approximately 8-10 cm) or if the swelling is still present and not improving at 48 hours. The practical guidance from AAAAI and clinical practice: a reaction larger than a quarter (about 2.5 cm) that persists beyond a few hours should be documented and reported. A reaction reaching palm size is a large local reaction (LLR) by clinical standards. Call the clinic on the same day if the swelling is significantly larger than expected, worsening after 24 hours instead of improving, accompanied by any warmth, streaking, or fever (which could suggest infection rather than an allergic reaction), or if any symptom appears beyond the injection arm. Never try to wait out a reaction that extends beyond the injection site — that is a systemic reaction requiring immediate evaluation.

This is one of the most genuinely contested questions in allergy immunotherapy practice. The evidence-based position — stated explicitly in the AAAAI/ACAAI Practice Parameter Third Update (Cox et al., JACI 2011), supported by Tankersley 2000 (n=12,926 injections) and Kelso 2004 — is that no dose adjustment is required for typical large local reactions, because no dose-adjustment policy did not increase systemic reaction rates. Yet a 2007 survey by Coop and Tankersley found that 91.9% of allergists still reduce or hold doses after large local reactions — deeply ingrained clinical habit that persists despite the evidence. Both perspectives have merit in practice: evidence-based no-adjustment preserves treatment velocity; clinical habit adjustments may reassure patients and address individual comfort. The key is that recurrent large local reactions — a pattern, not an isolated event — are more meaningfully associated with systemic reaction risk and warrant closer evaluation.

A single large local reaction does not reliably predict a subsequent systemic reaction. The 2011 AAAAI/ACAAI Practice Parameter explicitly states that published studies do not indicate an individual large local reaction is predictive of a subsequent systemic reaction. Tankersley 2000 (12,926 injections with a no-adjustment policy) found no increase in systemic reaction rates. However, a pattern of frequent or recurrent large local reactions tells a different story. The REPEAT Study (Calabria et al., Ann Allergy 2011) found that 41.7% of patients with recurrent large local reactions experienced at least one systemic reaction over follow-up, versus only 10.7% of patients without recurrent large local reactions. A pediatric cohort (Bahceci Erdem 2021) found a 3.32-fold increased systemic reaction risk after large local reactions. Current evidence supports a nuanced position: one LLR does not require dose adjustment, but a recurrent pattern warrants clinical reassessment.

Taking an antihistamine before an allergy shot can reduce the size and frequency of large local reactions. Reimers et al. (JACI 2000) demonstrated benefit for antihistamine premedication in reducing local reaction severity. Cetirizine 10 mg taken 1 hour before the injection is a commonly used protocol. However, the AAAAI/ACAAI Practice Parameter does not recommend routine antihistamine premedication for conventional SCIT, primarily because antihistamines may mask early cutaneous warning signs of a progressing systemic reaction — the generalized hives or itching that would prompt immediate staff intervention might be suppressed. For patients with consistently large local reactions that are significantly impacting their comfort or adherence to treatment, allergists may recommend premedication on a case-by-case basis, weighing the local reaction reduction benefit against the masking concern.

A late-phase local reaction is a second wave of swelling and induration at the allergy shot injection site that develops 6-12 hours after the injection, distinct from the immediate IgE-mediated wheal that occurs within 20-30 minutes. The late-phase response is driven by the migration of eosinophils and T-cells into the injection site, recruited by cytokines released during the immediate response. The late-phase swelling typically peaks at 24-48 hours and can be significantly larger than the immediate reaction — sometimes reaching palm size. This is the reaction that patients notice when they wake up the morning after a shot with a larger-than-expected swollen arm. Late-phase local reactions are not a sign of a systemic reaction; they are confined to the injection site. They are classified as large local reactions (LLRs) when they exceed 2.5 cm and are managed with ice, oral antihistamines, and elevation of the arm.

Bacterial infection at allergy shot injection sites is exceedingly rare and is not meaningfully addressed in the AAAAI/ACAAI surveillance literature, reflecting how uncommon it is in clinical practice. The sterile preparation of allergen extracts and standard subcutaneous injection technique create very low infection risk. However, patients sometimes confuse the warmth and redness of an allergic local reaction with the warmth and redness of infection. The distinguishing features of infection (cellulitis) rather than allergic local reaction include: expanding warmth and redness spreading beyond the initial reaction area over 24-48 hours rather than resolving; fever; red streaking from the injection site toward the lymph nodes; and pus or discharge. An allergic local reaction will typically be warmest and largest in the first 24-48 hours and then improve. Any skin changes worsening after 48 hours, accompanied by fever, warrant same-day clinical evaluation to exclude infection.